TABLE OF CONTENTS
Volume 72, Issue 1 (July 2002)
Pharmacodynamics and Drug Action |
Clinical Trials |
Pharmacogenetics and Genomics
Pharmacokinetics and Drug Disposition
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans FREE
Stéphane Mouly MD, Kenneth S. Lown MD, David Kornhauser MD, Jeffrey L. Joseph MS, William D. Fiske PhD, Irma H. Benedek PhD and Paul B. Watkins MD
Clin Pharmacol Ther 72: 1-9; doi:10.1067/mcp.2002.124519
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patientswith human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition FREE
Xiaoping Zhang PhD, Keith Nieforth PharmD, Jean-Marie Lang MD, Regine Rouzier-Panis MD, Jacques Reynes MD, Albert Dorr PhD, Stanley Kolis MS, Mark R. Stiles MS, Tosca Kinchelow MD and Indravadan H. Patel PhD
Clin Pharmacol Ther 72: 10-19; doi:10.1067/mcp.2002.125945
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans FREE
Stephen M. Eppler MS, Daniel L. Combs BS, Timothy D. Henry MD, John J. Lopez MD, Stephen G. Ellis MD, Joo-Hee Yi BS, Brian H. Annex MD, Edward R. McCluskey MD, PhD and Thomas F. Zioncheck PhD
Clin Pharmacol Ther 72: 20-32; doi:10.1067/mcp.2002.126179
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6
-hydroxycortisol
FREE
Hideki Ushiama MD, Hirotoshi Echizen MD, PhD, Shinobu Nachi BSc and Akihiro Ohnishi MD, PhD
Clin Pharmacol Ther 72: 33-43; doi:10.1067/mcp.2002.125559
Pharmacodynamics and Drug Action
In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model FREE
Asma A. Khan BDS, Jaime S. Brahim DDS, MS, Janet S. Rowan RN, MS and Raymond A. Dionne DDS, PhD
Clin Pharmacol Ther 72: 44-49; doi:10.1067/mcp.2002.125560
Clinical Trials
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet FREE
J. I. Schwartz PharmD, K. Vandormael MS, M. P. Malice PhD, R. N. Kalyani MS, K. C. Lasseter MD, G. B. Holmes PharmD, B. J. Gertz MD, PhD, K. M. Gottesdiener MD, M. Laurenzi MD, K.-J. Redfern PhD and K. Brune MD
Clin Pharmacol Ther 72: 50-61; doi:10.1067/mcp.2002.126182
Pharmacogenetics and Genomics
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2 FREE
Julia Kirchheiner MD, Ingolf Meineke PhD, Georg Freytag MS, Christian Meisel MD, Ivar Roots MD and Jürgen Brockmöller MD
Clin Pharmacol Ther 72: 62-75; doi:10.1067/mcp.2002.125726
Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans FREE
Andrea Gaedigk MS, PhD, L. DiAnne Bradford PhD, Kenda A. Marcucci BS and J. Steven Leeder PharmD, PhD
Clin Pharmacol Ther 72: 76-89; doi:10.1067/mcp.2002.125783
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 FREE
Kyoung-Ah Kim MS, Ji-Hong Shon MD, Ji-Young Park MD, Young-Ran Yoon MD, PhD, Min-Jung Kim MS, Doo-Hee Yun PhD, Moon-Kyung Kim MS, In-June Cha MD, PhD, Myung-Ho Hyun PhD and Jae-Gook Shin MD, PhD
Clin Pharmacol Ther 72: 90-99; doi:10.1067/mcp.2002.126176
